Testosterone levels in males with type 2 diabetes and their relationship with cardiovascular risk factors and cardiovascular disease

Journal of Sexual Medicine

Volumn 7, Issue 5, 2010, Pages 1954-1964

  Hernández Mijares, Antonio ^a,b   García Malpartida, Katherine ^a   Solá Izquierdo, Eva ^b   Bañuls, Celia ^c   Rocha, Milagros ^a   Gómez Martínez, Manuel Jesús ^a   Mármol, Rosario ^a   Víctor, Víctor Manuel ^a  

^a HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Cardiovascular Risk Factors; Hypogonadism; Metabolic Syndrome; Testosterone; Type 2 Diabetes

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; FOLLITROPIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; INSULIN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; LUTEINIZING HORMONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TRIACYLGLYCEROL;

ADULT; ANGIOCARDIOGRAPHY; ANKLE BRACHIAL INDEX; ARTERY DISEASE; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC INFLAMMATION; CORRELATIONAL STUDY; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; DOPPLER ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; ERECTILE DYSFUNCTION; FOLLITROPIN BLOOD LEVEL; HEART MUSCLE ISCHEMIA; HOLTER MONITORING; HOMEOSTASIS; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; KIDNEY DISEASE; LIPOPROTEIN BLOOD LEVEL; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETINOPATHY; SYSTOLIC BLOOD PRESSURE; TESTOSTERONE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; AGED; ARTERIAL OCCLUSIVE DISEASES; BLOOD; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PHYSIOLOGY; RISK FACTOR;

AGED; ARTERIAL OCCLUSIVE DISEASES; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; RISK FACTORS; TESTOSTERONE;

EID: 77953549931     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2010.01705.x     Document Type: Article

References (52)

1. Simon D, Preziosi P, Barrett-Connor E, Roger M, Saint-Paul M, Nahoul K, Papoz L. Interrelation between plasma testosterone and plasma insulin in healthy adult men: The Telecom Study. Diabetologia 1992, 35:173-7.
2. Oh JY, Barrett-Connor E, Weedick NM, Wingard DL. Endogenous sex hormones and the development of type 2 diabetes in older men and women. Diabetes Care 2002, 25:55-60.
3. Stellato RK, Feldman HA, Hamdy O, Horton ES, McKinlay JB. Testosterone, sex hormone binding globulin and the development of type 2 diabetes in middle-aged men. Diabetes Care 2000, 23:490-4.
4. Barrett-Connor E. Lower endogenous androgen levels and dyslipidemia in men with non insulin-dependent diabetes mellitus. Ann Intern Med 1992, 117:807-11.
5. Andersson B, Marin P, Lissner L, Vermeulen A, Bjorntorp P. Testosterone concentrations in women and men with NIDDM. Diabetes Care 1994, 17:405-11.
6. Dhindsa S, Prabhakar S, Sethi M, Bandyopadhyay A, Chaudhuri A, Dandona P. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab 2004, 89:5462-8.
7. Hak AE, Witteman JC, de Jong FH, Geerlings MI, Hofman A, Pols HA. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: The Rotterdam study. J Clin Endocrinol Metab 2002, 87:3632-9.
8. Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 2008, 93:68-75.
9. Fogari R, Preti P, Zoppi A, Fogari E, Rinaldi A, Corradi L, Mugellini A. Serum testosterone levels and arterial blood pressure in the elderly. Hypertens Res 2005, 28:625-30.
10. Barrett-Connor E, Khaw KT. Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study. Circulation 1988, 78:539-45.
11. Akishita M, Hashimoto M, Ohike Y, Ogawa S, Iijima K, Eto M, Ouchi Y. Low testosterone levels is an independent determinant of endothelial dysfunction in men. Hypertens Res 2007, 30:1029-34.
12. Malkin CJ, Pugh PJ, Jones RD, Jones TH, Channer KS. Testosterone as a protective factor against atherosclerosis-immunomodulation and influence upon plaque development and stability. J Endocrinol 2003, 178:373-80.
13. Wu FC, von Eckardstein A. Androgens and coronary artery disease. Endocr Rev 2003, 24:183-217.
14. Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morales A, Morley JE, Schulman C, Thompson IM, Weidner W, Wu FC. Investigation, treatment and monitoring of late onset hypogonadism in males. ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol 2008, 159:507-14.
15. Cappelleri JC, Rosen RC, Smith MD, Mishra A, Osterloh IH. Diagnostic evaluation of erectile dysfunction domain of the international index of erectile function. Urology 1999, 54:346-51.
16. Stevens RJ, Kothari V, Adler AI, Stratton IM, Holman RR. United Kingdom Prospective Diabetes Study (UKPDS) Group. The UKPDS risk engine: A model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci 2001, 101:671-9.
17. Gibbons RJ, Balady GJ, Bricker JT, Chaitman BR, Fletcher GF, Froelicher VF, Mark DB, McCallister BD, Mooss AN, O'Reilly MG, Winters WL, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Hiratzka LF, Jacobs AK, Russell RO, Smith SC. ACC/AHA 2002 guideline update for exercise testing: Summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). J Am Coll Cardiol 2002, 40:1531-40.
18. Klocke FJ, Baird MG, Lorell BH, Bateman TM, Messer JV, Berman DS, O'Gara PT, Carabello BA, Russell RO, Cerqueira MD, St John Sutton MG, DeMaria AN, Udelson JE, Kennedy JW, Verani MS, Williams KA, Antman EM, Smith SC, Alpert JS, Gregoratos G, Anderson JL, Hiratzka LF, Faxon DP, Hunt SA, Fuster V, Jacobs AK, Gibbons RJ, Russell RO. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging: Executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of cardiac Radionuclide Imaging). Circulation 2003, 108:1404-18.
19. Kapoor D, Aldred H, Clark S, Channer KS, Jones TH. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: Correlations with bioavailable testosterone and visceral adiposity. Diabetes Care 2007, 30:911-7.
20. Bettocchi C. Late onset hypogonadism (LOH): Incidence, diagnosis and short-term effects. Eur Urol Suppl 2005, 4:4-9.
21. Pasquali R, Casimirri F, De Iasio R, Mesini P, Boschi S, Chierici R, Flamia R, Biscotti M, Vicennati V. Insulin regulates testosterone and sex hormone-binding globulin concentrations in adult normal weight and obese men. J Clin Endocrinol Metab 1995, 80:654-8.
22. Laaksonen DE, Niskanen L, Punnonen K, Nyyssönen K, Tuomainen TP, Salonen R, Rauramaa R, Salonen JT. Sex hormones, inflammation and the metabolic syndrome: A population-based study. Eur J Endocrinol 2003, 149:601-8.
23. Corona G, Mannucci E, Fisher AD, Lotti F, Petrone L, Balercia G, Bandini E, Forti G, Maggi M. Low levels of androgens in men with erectile dysfunction and obesity. J Sex Med 2008, 5:2454-63.
24. Kapoor D, Malkin CJ, Channer KS, Jones TH. Adrogens, insulin resistance and vascular disease in men. Clin Endocrinol (Oxf) 2005, 63:239-50.
25. Mårin P, Holmäng S, Jönsson L, Sjöström L, Kvist H, Holm G, Lindstedt G, Björntorp P. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes Relat Metab Disord 1992, 16:991-7.
26. Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006, 91:1305-8.
27. Yialamas MA, Dwyer AA, Hanley E, Lee H, Pitteloud N, Hayes FJ. Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2007, 92:4254-9.
28. Pitteloud N, Mootha VK, Dwyer AA, Hardin M, Lee H, Eriksson KF, Tripathy D, Yialamas M, Groop L, Elahi D, Hayes FJ. Relationship between testosterone levels, insulin sensitivity, and mytocondrial function in men. Diabetes Care 2005, 28:1636-42.
29. Abate N, Haffner SM, Garg A, Peshock RM, Grundy SM. Sex steroid hormones, upper body obesity, and insulin resistance. J Clin Endocrinol Metab 2002, 87:4522-7.
30. Tsai EC, Matsumoto AM, Fujimoto WY, Boyko EJ. Association of bioavailable, free, and total testosterone with insulin resistance: Influence of sex hormone-binding globulin and body fat. Diabetes Care 2004, 27:861-8.
31. Yeap BB, Chubb SA, Hyde Z, Jamrozik K, Hankey GJ, Flicker L, Norman PE. Lower serum testosterone is independently associated with insulin resistance in non-diabetic older men: The health in men study. Eur J Endocrinol 2009, 161:591-8.
32. Nehra A. Erectile dysfunction and cardiovascular disease: Efficacy and safety of phosphodiesterase type 5 inhibitors in men with both conditions. Mayo Clin Proc 2009, 84:139-48.
33. Guay AT. Testosterone and erectile physiology. Aging Male 2006, 9:201-6.
34. Blute M, Hakimian P, Kashanian J, Shteynshluyger A, Lee M, Shabsigh R. Erectile dysfunction and testosterone deficiency. Front Horm Res 2009, 37:108-22.
35. Corona G, Mannucci E, Mansani R, Petrone L, Bartolini M, Giommi R, Mancini M, Forti G, Maggi M. Aging and pathogenesis of erectile dysfunction. Int J Impot Res 2004, 16:395-402.
36. Haddad RM, Kennedy CC, Caples SM, Tracz MJ, Boloña ER, Sideras K, Uraga MV, Erwin PJ, Montori VM. Testosterone and cardiovascular risk in men: A systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc 2007, 82:29-39.
37. Bhatia V, Chaudhuri A, Tomar R, Dandona P, Dhindsa S, Ghanim H, Dandona P. Low testosterone and high C-reactive protein concentrations predict low hematocrit in type 2 diabetes. Diabetes Care 2006, 29:2289-94.
38. Janand-Delenne B, Savin B, Habib G, Bory M, Vague P, Lassmann-Vague V. Silent myocardial Ischemia in patients with diabetes. Diabetes Care 1999, 22:1396-400.
39. Corona G, Mannucci E, Forti G, Maggi M. Hypogonadism, ED, metabolic syndrome and obesity: A pathological link supporting cardiovascular diseases. Int J Androl 2009, 32:587-98.
40. Khaw KT, Dowsett M, Folkerd E, Bingham S, Wareham N, Luben R, Welch A, Day N. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 2007, 116:2694-701.
41. Ponikowska B, Jsnkowska EA, Maj J, Wegrzynowska-Teodorczyk K, Biel B, Reczuch K, Borodulin-Nadzieja L, Banasiak W, Ponikowski P. Gonadal and adrenal androgen deficiencies as independent predictors of increased cardiovascular mortality in men with type II diabetes mellitus and stable coronary artery disease. Int J Cardiol 2009, Apr 21. [Epub ahead of print] doi:10.1016/j.ijcard.2009.03.072
42. Yeap BB, Hyde Z, Almeida OP, Norman PE, Chubb SA, Jamrozik K, Flicker L, Hankey GJ. Lower testosterone levels predict incident stroke and transient ischemic attack in older men. J Clin Endocrinol Metab 2009, 94:2353-9.
43. Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 2008, 93:68-75.
44. Simon D, Charles MA, Nahoul K, Orssaud G, Kremski J, Hully V, Joubert E, Papoz L, Eschwege E. Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: The Telecom study. J Clin Endocrinol Metab 1997, 82:682-5.
45. Barrett-Connor E, Khaw KT. Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study. Circulation 1988, 78:539-45.
46. Arnlöv J, Pencina MJ, Amin S, Nam BH, Benjamin EJ, Murabito JM, Wang TJ, Knapp PE, D'Agostino RB, Bhasin S, Vasan RS. Endogenous sex hormones and cardiovascular disease incidence in men. Ann Intern Med 2006, 145:176-84.
47. Marso SP, Hiatt WR. Peripheral arterial disease in patients with diabetes. J Am Coll Cardiol 2006, 47:921-9.
48. Kallio M, Forsblom C, Groop PH, Groop L, Lepäntalo M. Development of new peripheral arterial occlusive disease in patients with type 2 diabetes during a mean follow-up of 11 years. Diabetes Care 2003, 26:1241-5.
49. Puras E, Gutiérrez-Baz M, Cáncer S, Alfayete-García JM, de Benito-Fernandez L, Perera-Sabio M, Criado-Galan F, Hernandez-Mijares A. A study of the prevalence of peripheral arterial disease and diabetes in Spain. Angiología 2008, 60:317-26.
50. Kapoor D, Jones TH. Smoking and hormones in health and endocrine disorders. Eur J Endocrinol 2005, 152:491-9.
51. Roglio I, Giatti S, Pesaresi M, Bianchi R, Cavaletti G, Lauria G, Garcia-Segura LM, Melcangi RC. Neuroactive steroids and peripheral neuropathy. Brain Res Rev 2008, 57:460-9.
52. Stanworth RD, Kapoor D, Channer KS, Jones TH. Statin therapy is associated with lower total but not bioavailable or free testosterone in men with type 2 diabetes. Diabetes Care 2009, 32:541-6.